Pacira Pharmaceuticals (PCRX) PT Set at $55.00 by HC Wainwright

Pacira Pharmaceuticals (NASDAQ:PCRX) has been given a $55.00 price target by investment analysts at HC Wainwright in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 18.66% from the company’s current price.

A number of other research analysts also recently weighed in on the company. JPMorgan Chase & Co. reissued a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday. Canaccord Genuity set a $46.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. Royal Bank of Canada set a $54.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. Leerink Swann assumed coverage on Pacira Pharmaceuticals in a research report on Tuesday. They issued a “market perform” rating and a $46.00 price target for the company. Finally, BidaskClub upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $49.00.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded up $0.05 during trading on Thursday, reaching $46.35. The company’s stock had a trading volume of 1,064,500 shares, compared to its average volume of 928,800. The company has a market capitalization of $1,740.00, a P/E ratio of -35.38 and a beta of 2.20. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals has a twelve month low of $29.81 and a twelve month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.15. The firm had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 earnings per share. equities analysts expect that Pacira Pharmaceuticals will post -0.85 EPS for the current fiscal year.

In other news, SVP James B. Jones sold 850 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $41.11, for a total value of $34,943.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kristen Marie Williams sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the chief accounting officer now directly owns 23,455 shares of the company’s stock, valued at $938,200. The disclosure for this sale can be found here. Insiders have sold a total of 70,075 shares of company stock valued at $2,707,452 in the last 90 days. 6.60% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of PCRX. HealthCor Management L.P. lifted its stake in shares of Pacira Pharmaceuticals by 63.1% in the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock valued at $85,564,000 after purchasing an additional 693,799 shares during the last quarter. Eaton Vance Management bought a new stake in shares of Pacira Pharmaceuticals during the 2nd quarter worth approximately $19,519,000. Mesirow Financial Investment Management Equity Management bought a new stake in shares of Pacira Pharmaceuticals during the 3rd quarter worth approximately $14,671,000. Stonepine Capital Management LLC bought a new stake in shares of Pacira Pharmaceuticals during the 3rd quarter worth approximately $14,089,000. Finally, Epoch Investment Partners Inc. lifted its stake in shares of Pacira Pharmaceuticals by 195.7% during the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after acquiring an additional 354,728 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/04/pacira-pharmaceuticals-pcrx-pt-set-at-55-00-by-hc-wainwright.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply